INTRODUCTION
In a previous analysis of pooled data from 11 randomized, controlled trials examining the efficacy of the oral phosphodiesterase type 5 (PDE5) inhibitor tadalafil in different clinical subpopulations, including men over 65 years, men with diabetes mellitus, and men with severe erectile dysfunction (ED), 1 it was noted that, in most groups studied, tadalafil 20 mg showed numerically greater improvement in erectile function compared with tadalafil 10 mg. However, the doses were not compared statistically, and, to our knowledge, significantly superior clinical responses to a hig her dose of a PDE5 inhibitor compared with a lower dose in ED clinical subpopulations have not been demonstrated.
The chief objective of the current analysis was to determine the comparative efficacy and tolerability of tadalafil 10 mg and 20 mg in a subpopulation of men with severe ED from a recent Japanese study. 2 Because the Japanese study was originally designed to detect differences between tadalafil and placebo rather than between tadalafil doses, there was a risk of encountering type II error (i.e., the result could lack statistical significance despite numerical superiority). Thus, we also examined (post hoc) efficacy data pooled from the only other tadalafil studies that examined both 10-and 20-mg doses using the same study design [three placebo-controlled trials (3 PCTs)]. [3] [4] [5] This pooleddata analysis was performed to increase the power of detecting a difference between the 10-and 20-mg doses in the subgroup of men with severe ED, should such a difference
exist, and to demonstrate the repeatability of the efficacy results reported for Japanese men.
To supplement these analyses and identify potential reasons for suboptimal treatment effects with tadalafil in patients with severe ED, we performed post-hoc analyses concerning the presence of organic ED and/or comorbidities that might compromise neurovascular function in Japanese patients. These analyses also were conducted to help identify patients with severe ED to whom tadalafil 20 mg might be prescribed.
METHODS

Study Design
This prespecified subgroup analysis was conducted to compare the efficacy of tadalafil 20 mg and tadalafil 10 mg for severe ED patients involved in a multicenter, randomized, double-blind, parallel-group, placebo-controlled study recently conducted in Japan (Study # H6D -MC-LVDI). 2 Severe ED was defined as a score of 1-10 on the International Index of Erectile Function (IIEF) erectile function (EF) domain after a 4-week treatment-free screening and run-in phase. 6, 7 Primary efficacy endpoints for this study have been reported.
2
The pooled-data analysis (3 PCTs) contained efficacy and tolerability data from three multicenter, randomized, double-blind, parallel-group, placebo-controlled trials conducted in China, Philippines, and Singapore (Study # H6D -MC-LVDY) 3 ; Taiwan (Study # H6D-MC-LVCO) 4 ; and Canada (Study # H6-MC-LVDJ). 5 These trials also were designed to detect differences between tadalafil and placebo rather than between tadalafil doses.
The study design and eligibility criteria for all four of these trials have been published elsewhere. [2] [3] [4] [5] ED severity was determined by the IIEF EF domain score. Three categories were adapted from Cappelleri 7 : mild (score of 17-30), moderate (11) (12) (13) (14) (15) (16) , and severe (1-10). Patients were randomly allocated in a 1:1:1 or 1:2:2 ratio (placebo:tada lafil 10 mg:tadalafil 20 mg) to treatment with placebo or tadalafil for up to 12 weeks. In the Japanese study, tadalafil 5 mg also was evaluated; however, data for this dose are not included here because the Japanese study did not assess tadalafil 5 mg as a primary efficacy endpoint, and the 3 PCTs did not include tadalafil 5 mg. [2] [3] [4] [5] In each study, informed consent was obtained from each patient prior to participation, and both the informed-consent document and study protocols were reviewed and approved by responsible institutional review boards.
Outcome Measures
Efficacy
There were three co- 
Tolerability
The tolerability of tadalafil was assessed throughout the treatment period by recording adverse events originally volunteered by patients after non-leading questions by the investigators. Treatment-emergent adverse events for each of the four studies have been reported previously.
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Statistics
The effects of tadalafil 20 mg on erectile function and on frequencies of treatment -emergent adverse events were compared with the effects of tadalafil 10 mg in patients with severe ED in the Japanese study, patients with severe ED in the 3 PCTs, and in the overall populations.
All patients with a baseline and at least one post-baseline observation were included in the efficacy analyses. For the IIEF EF domain analysis, missing endpoint data were imputed with the most recent non-missing post-baseline value using the last observation carried forward convention. Efficacy analyses were performed on an intentto-treat basis. Changes from baseline to endpoint were evaluated using an analysis of covariance (ANCOVA) model including effects for baseline, treatment group, and site.
For the 3 PCTS, an effect for study was included instead of site in the model mentioned above. In addition, the model included therapy-by-baseline interaction if P<0.10.
Treatment group differences were evaluated within the ANCOVA model by contrasting model-based LS means. All tests of statistical significance were two-tailed at a=0.05.
Given the exploratory nature of these analyses and the associated low power of tests, no adjustments for multiplicity were utilized.
Analyses comparing the incidences of treatment-emergent adverse events across treatment groups were performed using ? 2 tests.
RESULTS
Patient Characteristics
Among 258 randomized patients in the Japa nese study, 99 had severe ED: 33 each in the placebo, tadalafil 10 mg, and tadalafil 20 mg groups. Among 816 total patients in the 3 PCTs, 256 had severe ED: 77 in the placebo group, 95 in the tadalafil 10 mg group, and 84 in the tadalafil 20 mg group. Baseline characteristics of patients with severe ED in the Japanese study are summarized in Table 1 .
Efficacy
Primary Efficacy Measures
Japanese study. Among patients with severe ED, changes from baseline to endpoint in all three efficacy measures were numerically higher (improved), although not statistically significantly higher, for tadalafil 20 mg compared with tadalafil 10 mg (Figure 1 ). The differences between treatment groups in the overall Japanese population were less pronounced.
Patients with severe ED in the pooled 3 PCT data. When a subgroup analysis of men with severe ED was conducted for each individual study within the 3 PCT data set, changes in the three co-primary endpoints were numerically greater for the 20-mg compared with the 10-mg dos e, though the differences were not statistically significant 
Secondary Efficacy Measures
In the Japanese study, the change from baseline in per-patient percent "yes"
responses to SEP5 in patients with severe ED was significantly greater for patients taking tadalafil 20 mg compared with 10 mg (50.9% vs. 28.0%, P=0.005). This difference was less pronounced in the overall Japanese populatio n (47.9% vs 39.3%, P=0.076).
The proportion of patients with severe ED in the Japanese study with a normal IIEF EF domain score (>26) at endpoint was numerically greater in patients taking tadalafil 20 mg compared with 10 mg (54.6% vs. 39.4%, respectively ; P=0.218). The proportions of patients in the overall Japanese population with normal IIEF EF domain scores were similar between tadalafil 20 mg and 10 mg (Figure 2 ).
Among Japanese patients with severe ED and organic comorbidities, most (70.6%) had inadequate treatment effects to tadalafil 10 mg as assessed by both IIEF EF domain score and SEP3 ( Table 2) . On the other hand, the number (%) of patients with adequate treatment effects to tadalafil 20 mg in the presence of comorbidities increased, such that more than half (55.6%) of patients had adequate treatment effects to tadalafil 20 mg.
As shown in Figure 3 , Japanese patients with severe ED and organic comorbidity exhibited a dose response in LS mean changes (improvements) from baseline to endpoint in the IIEF EF domain score (Figure 3A) , as well as in mean per -patient proportions of "yes" responses to SEP2 ( Figure 3B ) and SEP3 (Figure 3C) , over the dose range tadalafil 10-20 mg. On the other hand, patients with severe ED but without these comorbidities did not exhibit a dose response across all three endpoints.
Tolerability
No patient with severe ED who received tadalafil 20 mg in any study discontinued treatment because of adverse events. [2] [3] [4] [5] Two (0.8%) of 245 patients (all studies) with severe ED discontinued because of adverse events (both in the tadalafil 10 mg group). [2] [3] [4] [5] There were no significant differences between treatment groups in frequencies of treatment-emergent adverse events among patients with severe ED in the Japanese study (Table 3) . However, among men with severe ED in the 3 PCTs, there were significant differences between treatment groups in the frequencies of dizziness (0% for placebo, 2.1% for tadalafil 10 mg, and 7.1% for tadalafil 20 mg; P=0.026) and dyspepsia (0% for placebo, 5.3% for tadalafil 10 mg, and 14.3% for tadalafil 20 mg;
P=0.001; data not shown). In pairwise comparisons between tadalafil 10 mg and 20 mg, only dyspepsia showed a significant difference between doses (P=0.040; data not shown). ED and organic comorbidities did not derive adequate treatment effects from tadalafil 10 mg but were more likely to do so when receiving the higher dose.
DISCUSSION
There was no increase in the incidence or severity of treatment-emergent adverse events for Japanese patients with severe ED taking tadalafil 20 mg compared with 10 mg, and no patient with severe ED who received tadalafil 20 mg discontinued because of adverse events. The findings of no significant differences in adverse events between doses in men with severe ED in the Japanese study may have been due to insufficient power to detect differences, because ED clinical studies are almost invariably powered for efficacy outcomes, not adverse events. Tadalafil was well tolerated at both doses, with only 2 (0.8%) of 245 men with severe ED discontinuing treatment because of adverse events (both in the tadalafil 10 mg group).
In the Japanese study, both tadalafil doses showed significant improvement in erectile function in men with severe ED compared with placebo, but tadalafil 20 mg showed numerically greater improvements in efficacy measures compared with tadalafil 10 mg for patients with severe ED, although statistical significance was not reached (likely because of type II error). As noted, the original study was not powered to detect a difference between tadalafil doses in the total population or in the subset of men with severe ED (N=99). That a type II error occurred is supported by the results of the analysis of the 3 PCTs. When the data from these studies were pooled (N=256), the efficacy endpoints were statistically greater for tadalafil 20 mg compared with 10 mg for patients with severe ED.
According to our analyses, a large proportion of patients with severe ED together with organic comorbidities, including diabetes mellitus, hypertension, hyperlipidemia, or atherosclerosis-induced disease, did not obtain adequate treatment effects using tadalafil 10 mg but did achieve adequate efficacy when the tadalafil dose was 20 mg. The change from baseline to endpoint in each efficacy parameter among patients receiving tadalafil 10 mg was modest and clearly different from the change observed in patients receiving tadalafil 20 mg. Therefore, when treating men with severe ED and organic comorbidities , strong consideration should be given to treatment with tadalafil 20 mg.
Certain limitations of our study should be noted. The Japanese study and the 
